Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 17011 [2017-06984]
Download as PDF
Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, May 9, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Formative Study of Patient Navigators
with the National Breast and Cervical
Cancer Early Detection Program
(NBCCEDP) and the Colorectal Cancer
Control Program (CRCCP)’’, SIP 17–003
and ‘‘Assessing the Lifetime Economic
Burden in Younger, Midlife, and Older
Women with Metastatic Breast Cancer’’,
SIP 17–004.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06979 Filed 4–6–17; 8:45 am]
a.m.–5:00 p.m., EDT, May 12, 2017
(Closed).
Place: The Georgian Terrace, 659
Peachtree Street NE., Atlanta, Georgia
30308.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Research Grant for Preventing Violence
and Violence Related Injury (R01)’’,
RFA–CE–17–003.
Contact Person for More Information:
Kimberly Leeks, Ph.D., M.P.H.,
Scientific Review Officer, CDC, 4770
Buford Highway NE., Mailstop F78,
Atlanta, Georgia 30341–3717,
Telephone: (770) 488–5964.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
ACTION:
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Antimicrobial Drugs
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public. FDA
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06984 Filed 4–6–17; 8:45 am]
BILLING CODE 4163–18–P
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2017–N–1813]
Centers for Disease Control and
Prevention
nlaroche on DSK30NT082PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement,
RFA–CE–17–003, Research Grant for
Preventing Violence and Violence
Related Injury (R01).
Times and Dates: 08:00 a.m.–5:00
p.m., EDT, May 11, 2017 (Closed) 8:00
VerDate Sep<11>2014
17:15 Apr 06, 2017
Jkt 241001
is establishing a docket for public
comment on this document.
DATES: The meeting will be held on
April 13, 2017, from 8:30 a.m. to 5 p.m.
The docket number is FDA–2017–N–
1813. The docket will close on April 12,
2017. Comments received on or before
April 10, 2017, will be provided to the
committee. Comments received after
that date will be taken into
consideration by the Agency.
ADDRESSES: Tommy Douglas Conference
Center, the Ballroom, 10000 New
Hampshire Ave., Silver Spring, MD
20903. The conference center’s
telephone number is 240–645–4000.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
You may submit comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
17011
Antimicrobial Drugs Advisory
Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice; establishment of public
docket; request for comments.
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
E:\FR\FM\07APN1.SGM
07APN1
Agencies
[Federal Register Volume 82, Number 66 (Friday, April 7, 2017)]
[Notices]
[Page 17011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06984]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement, RFA-CE-
17-003, Research Grant for Preventing Violence and Violence Related
Injury (R01).
Times and Dates: 08:00 a.m.-5:00 p.m., EDT, May 11, 2017 (Closed)
8:00 a.m.-5:00 p.m., EDT, May 12, 2017 (Closed).
Place: The Georgian Terrace, 659 Peachtree Street NE., Atlanta,
Georgia 30308.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Research Grant for Preventing Violence and Violence Related Injury
(R01)'', RFA-CE-17-003.
Contact Person for More Information: Kimberly Leeks, Ph.D., M.P.H.,
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F78,
Atlanta, Georgia 30341-3717, Telephone: (770) 488-5964.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-06984 Filed 4-6-17; 8:45 am]
BILLING CODE 4163-18-P